Plavix generic makers agonize over market entry

Korea's 17 generic makers won the right to market Plavix (clopidogrel bisulfate) in a recent patent lawsuit, several drug makers who will join the lucrative market with their newly modified medicines are keen on the listing of the national health insurance.

Last October, Chong Kun Dang's Prigrel (clopidogrel resignate) failed to get listed in the health-insurance eligible category as the dru...